stoxline Quote Chart Rank Option Currency Glossary
  
BrainsWay Ltd. (BWAY)
8.48  -0.25 (-2.86%)    11-20 16:00
Open: 8.72
High: 8.72
Volume: 109,517
  
Pre. Close: 8.73
Low: 8.455
Market Cap: 333(M)
Technical analysis
2026-11-20 4:43:07 PM
Short term     
Mid term     
Targets 6-month :  12.61 1-year :  14.3
Resists First :  10.8 Second :  12.25
Pivot price 10.25
Supports First :  8.45 Second :  7.03
MAs MA(5) :  8.93 MA(20) :  10.56
MA(100) :  13.42 MA(250) :  13.06
MACD MACD :  -0.9 Signal :  -0.7
%K %D K(14,3) :  1.5 D(3) :  2.5
RSI RSI(14): 27.9
52-week High :  17.39 Low :  7.3
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BWAY ] has closed above bottom band by 6.5%. Bollinger Bands are 93.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.78 - 8.86 8.86 - 8.91
Low: 8.28 - 8.39 8.39 - 8.45
Close: 8.36 - 8.53 8.53 - 8.64
Company Description

Established in Jerusalem, Israel, in 2003, BrainsWay Ltd. specializes globally in creating and distributing advanced, non-invasive neurostimulation therapies designed to address a wide array of mental health and neurological conditions. The company's primary innovation is its Deep Transcranial Magnetic Stimulation (dTMS) platform, which offers treatment for disorders including major and anxious depression, obsessive-compulsive disorder, nicotine addiction, bipolar disorder, post-traumatic stress disorder, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's solutions are primarily adopted by psychiatric practitioners, hospitals, and medical centers across the United States, Europe, Israel, and other international markets.

Headline News

Thu, 10 Sep 2026
BrainsWay’s (BWAY) Growth Streak Just Got Harder To Ignore - Yahoo Finance

Thu, 27 Aug 2026
Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High? - Yahoo Finance

Mon, 17 Aug 2026
Brainsway (BWAY) Upgraded to Buy: Here's Why - Yahoo Finance

Thu, 13 Aug 2026
BrainsWay: Market Saturation And Competition Could Be Issues (NASDAQ:BWAY) - Seeking Alpha

Tue, 26 May 2026
BWAY - Brainsway Ltd ADR Stock Price and Quote - Finviz

Mon, 13 Apr 2026
Brainsway (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why - qz.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Specialties
Shares Out 40 (M)
Shares Float 24 (M)
Held by Insiders 6 (%)
Held by Institutions 29.3 (%)
Shares Short 226 (K)
Shares Short P.Month 200 (K)
Stock Financials
EPS 0.23
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.97
Profit Margin 15.5 %
Operating Margin 13.9 %
Return on Assets (ttm) 4 %
Return on Equity (ttm) 12.8 %
Qtrly Rev. Growth 35.4 %
Gross Profit (p.s.) 1.13
Sales Per Share 1.5
EBITDA (p.s.) 0.21
Qtrly Earnings Growth 59.7 %
Operating Cash Flow 8 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio 36.86
PEG Ratio 0
Price to Book value 4.3
Price to Sales 5.62
Price to Cash Flow 45.08
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android